Highly Selective Targeting of Pancreatic Cancer in the Liver with a Near-Infrared Anti-MUC5AC Probe in a PDOX Mouse Model: A Proof-of-Concept Study

Michael A. Turner, Kristin E. Cox, Nicholas Neel, Siamak Amirfakhri, Hiroto Nishino, Bryan M. Clary, Mojgan Hosseini, Gopalakrishnan Natarajan, Kavita Mallya, Aaron M. Mohs, Robert M. Hoffman, Surinder K. Batra, Michael Bouvet

Research output: Contribution to journalArticlepeer-review

Abstract

Accurately identifying metastatic disease is critical to directing the appropriate treatment in pancreatic cancer. Mucin 5AC is overexpressed in pancreatic cancer but absent in normal pancreas tissue. The present proof-of-concept study demonstrates the efficacy of an anti-mucin 5AC antibody conjugated to an IR800 dye (MUC5AC-IR800) to preferentially label a liver metastasis of pancreatic cancer (Panc Met) in a unique patient-derived orthotopic xenograft (PDOX) model. In orthotopic models, the mean tumor to background ratio was 1.787 (SD ± 0.336), and immunohistochemistry confirmed the expression of MUC5AC within tumor cells. MUC5AC-IR800 provides distinct visualization of pancreatic cancer liver metastasis in a PDOX mouse model, demonstrating its potential utility in staging laparoscopy and fluorescence-guided surgery.

Original languageEnglish (US)
Article number857
JournalJournal of Personalized Medicine
Volume13
Issue number5
DOIs
StatePublished - May 2023

Keywords

  • fluorescent antibody
  • imaging
  • liver metastasis
  • mucin
  • pancreatic cancer
  • selective targeting

ASJC Scopus subject areas

  • Medicine (miscellaneous)

Fingerprint

Dive into the research topics of 'Highly Selective Targeting of Pancreatic Cancer in the Liver with a Near-Infrared Anti-MUC5AC Probe in a PDOX Mouse Model: A Proof-of-Concept Study'. Together they form a unique fingerprint.

Cite this